Courses

Heart disease continues to be the leading cause of mortality in Europe. Despite advances in prevention and therapy, each year cardiovascular disease (CVD) causes over 1.8 million deaths in the European Union (EU).  CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU, is the main cause of death in men in all ...
View Course

This CE activity will highlight recent advances in the usage of therapeutic agents for the reversal of oral anticoagulants, particularly in patients with life-threatening bleeds. The expert faculty, Dr. Charles V. Pollack Jr., will review emerging therapies for patients with uncontrolled bleeding as well as discuss the latest data on current therapeutic options for the reversal prior to urgent of ...
View Course

This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight advanced strategies for improving cardiovascular disease (CVD) outcomes in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD). The expert faculty, chaired by Dr. Christopher P. Cannon, will first provide an introduction and state of the science ...
View Course

This CME program will highlight recent advances in intensive antiplatelet therapy to improve outcomes in patients with acute coronary syndrome (ACS). The expert faculty, led by Dr. Christopher P. Cannon, will review platelet inhibition science as well as unmet needs in ACS. Following, recent clinical trial data, including outcomes data, will be analyzed and clinical relevance debated in an interactive ...
View Course

This continuing education activity is derived from content presented at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada. The program will highlight recent advances in antiplatelet therapeutics for acute coronary syndrome. The expert faculty will analyze current guidelines and provide insight into best approaches for developing effective patient-specific treatment plans that include the clinical pharmacy team ...
View Course

This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight new therapeutic options for acute and chronic hyperkalemia. The expert faculty, led by Dr. Charles V. Pollack, Jr., will first provide an introduction and state of the science of hyperkalemia, including risk assessment and disease burden. Recent trial data of ...
View Course

This CME activity will discuss recent advances in the treatment and management of patients with pulmonary arterial hypertension (PAH). The expert faculty will provide learners with a scientific update regarding current evidence-based guidelines and appropriate diagnostic strategies. Recent clinical trial data of new and emerging therapeutic options for the treatment of PAH will be reviewed. The faculty will also discuss ...
View Course

In this module of a Four-Part Expert Interview Series, Inderjit Singh, MBChB, BMedSci, MRCP, along with Aaron B. Waxman, MD, PhD, course chair, will provide a scientific update of pulmonary arterial hypertension (PAH), including the evolution of therapeutic options. The clinical relevance of various precision PAH therapeutics will be debated, among other topics. The role of exercise hemodynamics in achieving ...
View Course

In this module of a Four-Part Expert Interview Series, Jeffrey Voner, MSHS, MPH, PA-C, DFAAPA, along with Aaron B. Waxman, MD, PhD, course chair, will outline recent treatment data for pulmonary arterial hypertension (PAH) as it relates to interprofessional patient care. Best practices for managing heart failure will be reviewed along with potential treatment directions after a confirmed diagnosis of ...
View Course

In this module of a Four-Part Expert Interview Series, R. James White, MD, along with Aaron B. Waxman, MD, PhD, course chair, will review advancements in the treatment and management of pulmonary arterial hypertension (PAH). The pipeline of available therapies will be relayed, along with strategies for selecting optimal single/combination therapies for PAH patients. The clinical relevance of recent treatment ...
View Course